# Josh Hawley

Type: Person

Source: GetYourBrief — https://getyourbrief.com/entity/josh-hawley
Canonical HTML page: https://getyourbrief.com/entity/josh-hawley

## Timeline

- **2026-03-13**: Missouri Stay Request — DOJ files request in Missouri court to pause litigation pending FDA review.
- **2026-03-13**: DOJ Missouri Filing — DOJ quietly asks the Missouri court to pause proceedings pending FDA review.
- **2026-03-12**: Missouri Pause Request — DOJ files a request in federal court to pause the Missouri-led lawsuit citing an ongoing FDA review.
- **2026-03-11**: Legislative Action — Senator Josh Hawley introduces a Senate bill to outright ban the abortion pill.
- **2026-03-11**: Legislative Action — Sen. Josh Hawley introduces a Senate bill to outright ban the abortion pill.
- **2026-03-11**: Hawley Federal Bill — Senator Josh Hawley introduces a bill in the Senate to ban mifepristone nationwide.
- **2026-01-20**: Louisiana Request — DOJ asks Louisiana court to pause a similar lawsuit; request is largely ignored by the state.
- **2026-01-20**: Louisiana Precedent — DOJ unsuccessfully asks Louisiana to pause its separate anti-abortion lawsuit.
- **2026-01-15**: Louisiana Pause Request — DOJ asks Louisiana to pause its separate lawsuit; request is rejected by AG Liz Murrill.
- **2025-11-15**: Amended Complaint — AG Catherine Hanaway files amended complaint targeting mail-order abortion drugs.
- **2025-11-15**: Amended Complaint — AG Catherine Hanaway adds claims that mail-order drugs are dangerous without in-person visits.
- **2025-10-01**: Lawsuit Filed — Missouri, Kansas, and Idaho file suit against the FDA over mifepristone approval.
- **2025-10-01**: Lawsuit Filed — Missouri, Kansas, and Idaho file suit against the FDA over mifepristone regulations.
- **2025-10-01**: Missouri Lawsuit Filed — Missouri, Kansas, and Idaho file suit against the FDA to restrict mifepristone access.

## Recent coverage (3 stories, network-wide)

### DOJ Seeks Pause in Missouri Mifepristone Suit Amid FDA Review Strategy
2026-03-13 00:35:09 · Sector: bio · Sentiment: Negative · Impact: 8/10 · Sources: 2

The Department of Justice has requested a federal court to pause a multi-state lawsuit against the FDA regarding the abortion pill mifepristone. The move suggests a strategic effort to allow the FDA to conduct its own internal review of the drug's safety and distribution protocols.
Full story: https://getbiobrief.com/story/doj-missouri-mifepristone-lawsuit-pause

### DOJ Requests Pause in Missouri Mifepristone Lawsuit Citing Internal FDA Review
2026-03-13 00:34:35 · Sector: health · Sentiment: Negative · Impact: 8/10 · Sources: 2

The U.S. Department of Justice has requested a federal court in Missouri to pause or dismiss a lawsuit targeting the FDA's approval of mifepristone, citing an ongoing internal agency review. This move reflects a strategic effort by the administration to manage high-stakes litigation over medication abortion and telehealth access ahead of the 2026 midterms.
Full story: https://gethealthbrief.com/story/doj-missouri-mifepristone-lawsuit-pause

### DOJ Seeks Strategic Pause in State-Led Mifepristone Litigation Amid FDA Review
2026-03-13 00:34:01 · Sector: legal · Sentiment: Negative · Impact: 8/10 · Sources: 2

The U.S. Department of Justice has requested federal courts in Missouri to pause litigation challenging the FDA's approval of mifepristone, citing an ongoing internal agency review. This tactical shift suggests a preference for administrative rulemaking over high-profile court battles as the administration navigates the legal complexities of reproductive health regulation.
Full story: https://getlegalbrief.com/story/doj-mifepristone-litigation-stay-missouri

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.